{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Diseases&page=12", "query": { "condition": "Multiple Diseases", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 12225, "total_pages": 1223, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Diseases&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Diseases&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-06T01:25:54.604Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00855920", "title": "Study Utilizing Rilonacept in Gout Exacerbations", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Gout Flare" ], "interventions": [ { "name": "Rilonacept", "type": "DRUG" }, { "name": "Indomethacin", "type": "DRUG" }, { "name": "Placebo (for Indomethacin)", "type": "OTHER" }, { "name": "Placebo (for Rilonacept)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 225, "start_date": "2009-03", "completion_date": "2010-02", "has_results": true, "last_update_posted_date": "2017-04-28", "last_synced_at": "2026-11-06T01:25:54.604Z", "location_count": 44, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sierra Vista", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00855920" }, { "nct_id": "NCT01850524", "title": "IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Ixazomib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Millennium Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 705, "start_date": "2013-04-29", "completion_date": "2022-06-24", "has_results": true, "last_update_posted_date": "2023-07-21", "last_synced_at": "2026-11-06T01:25:54.604Z", "location_count": 78, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 75 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01850524" }, { "nct_id": "NCT02985879", "title": "A Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Subjects With Progressive Supranuclear Palsy (PSP)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Progressive Supranuclear Palsy" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "ABBV-8E12", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 378, "start_date": "2016-12-12", "completion_date": "2019-11-20", "has_results": true, "last_update_posted_date": "2021-02-03", "last_synced_at": "2026-11-06T01:25:54.604Z", "location_count": 27, "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Beverly Hills, California + 22 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02985879" }, { "nct_id": "NCT02393248", "title": "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer", "Solid Tumor", "Gastric Cancer", "Urothelial Cancer", "Endometrial Cancer", "Multiple Myeloma", "Myeloproliferative Neoplasms", "Breast Cancer", "Cholangiocarcinoma", "UC", "MPN" ], "interventions": [ { "name": "Pemigatinib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 201, "start_date": "2015-02-27", "completion_date": "2021-12-17", "has_results": true, "last_update_posted_date": "2023-01-06", "last_synced_at": "2026-11-06T01:25:54.604Z", "location_count": 19, "location_summary": "Birmingham, Alabama • West Hollywood, California • New Haven, Connecticut + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "West Hollywood", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Port Saint Lucie", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02393248" }, { "nct_id": "NCT01951885", "title": "Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Myelogenous Leukemia", "Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia", "Acute Biphenotypic Leukemia", "Myelodysplastic Syndrome", "Myeloproliferative Neoplasm", "Non-Hodgkin Lymphoma", "Hodgkins Disease", "Chronic Lymphocytic Leukemia", "Multiple Myeloma" ], "interventions": [ { "name": "tacrolimus", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "Methotrexate (low dose)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 101, "start_date": "2014-07-07", "completion_date": "2021-08-11", "has_results": true, "last_update_posted_date": "2023-09-11", "last_synced_at": "2026-11-06T01:25:54.604Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01951885" }, { "nct_id": "NCT05467176", "title": "A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Relugolix", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 999, "start_date": "2022-10-04", "completion_date": "2026-06-30", "has_results": false, "last_update_posted_date": "2026-07-13", "last_synced_at": "2026-11-06T01:25:54.604Z", "location_count": 96, "location_summary": "Homewood, Alabama • Mobile, Alabama • Phoenix, Arizona + 81 more", "locations": [ { "city": "Homewood", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05467176" }, { "nct_id": "NCT00242268", "title": "A Safety Study of Combination Treatment With Avonex and Zocor in Relapsing Remitting Multiple Sclerosis", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsing Remitting Multiple Sclerosis" ], "interventions": [ { "name": "Simvastatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alabama Neurology Associates, PC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 30, "start_date": "2005-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2005-12-07", "last_synced_at": "2026-11-06T01:25:54.604Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00242268" }, { "nct_id": "NCT07280468", "title": "Endotype DIrected Treatment for OSA in Down Syndrome", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Obstructive Sleep Apnea (OSA)", "Down Syndrome" ], "interventions": [ { "name": "ato-oxy", "type": "DRUG" }, { "name": "Oxygen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": null, "sex": "ALL", "summary": "6 Years and older" }, "enrollment_count": 200, "start_date": "2026-03-14", "completion_date": "2030-01", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-11-06T01:25:54.604Z", "location_count": 5, "location_summary": "Tucson, Arizona • San Diego, California • Miami, Florida + 2 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Park Ridge", "state": "Illinois" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07280468" }, { "nct_id": "NCT00754013", "title": "Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Down Syndrome", "Cognitive Dysfunction" ], "interventions": [ { "name": "Aricept (Donepezil hydrochloride)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "10 Years", "sex": "ALL", "summary": "6 Years to 10 Years" }, "enrollment_count": 9, "start_date": "2008-09", "completion_date": "2008-12", "has_results": true, "last_update_posted_date": "2020-01-28", "last_synced_at": "2026-11-06T01:25:54.604Z", "location_count": 2, "location_summary": "San Antonio, Texas • Herndon, Virginia", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "Herndon", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00754013" }, { "nct_id": "NCT07032662", "title": "Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Inflammatory Demyelinating Polyneuropathy" ], "interventions": [ { "name": "Imeroprubart", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immunovant Sciences GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 162, "start_date": "2025-03-18", "completion_date": "2030-05", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-11-06T01:25:54.604Z", "location_count": 33, "location_summary": "Tucson, Arizona • Carlsbad, California • Mission Hills, California + 28 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Carlsbad", "state": "California" }, { "city": "Mission Hills", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Rancho Mirage", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07032662" } ] }